Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Outline of Final Research Achievements |
Murine sclerodermatous chronic graft-versus-host disease (Scl-cGVHD) is a model for human Scl-cGVHD and systemic sclerosis (SSc). Syk is a protein tyrosine kinase that has an important role in transmitting signals from a variety of cell surface receptors.This study aims to investigate the effect of a Syk inhibitor, R788, on Scl-cGVHD and role of Syk in patients with SSc. Allogeneic BMT increased Syk phosphorylation in T, B, and CD11b+ cells. Early administration of Syk inhibitor attenuated severity and fibrosis of Scl-cGVHD. Syk inhibitor also reduced skin mRNA expressions of IL-13, IL-17A, and TGF-β1. However,Syk phosphorylation in B cell of SSc patients was not increased compared with that of normal control. The current studies suggested that Syk inhibitor is a potential candidate for use in treating patients with Scl-cGVHD and SSc.
|